Source: Vogue
Fashion's spring 2027 turn toward sheer fabrics, lingerie-as-outerwear, and aggressive skin exposure reflects the body transformations happening at scale via Ozempic and competing GLP-1 medications. Designers are calibrating for a consumer base that is leaner, with visibly different proportions and newfound confidence in exposure. The entire supply chain—from fit models to proportioning formulas to silhouette investment—is recalibrating around a pharmaceutical-induced body standard. Brands are already making commercial bets on which body type will dominate their customer base over the next 18-24 months. GLP-1 adoption is now as material to fashion strategy as income inequality or globalization.